CN109069460A - 改进的药物制剂 - Google Patents

改进的药物制剂 Download PDF

Info

Publication number
CN109069460A
CN109069460A CN201780028973.8A CN201780028973A CN109069460A CN 109069460 A CN109069460 A CN 109069460A CN 201780028973 A CN201780028973 A CN 201780028973A CN 109069460 A CN109069460 A CN 109069460A
Authority
CN
China
Prior art keywords
poly
cellulose
pharmaceutically acceptable
copolymer
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780028973.8A
Other languages
English (en)
Chinese (zh)
Inventor
达夫·A·米勒
丹尼尔·J·埃伦伯格
桑德拉·U·席林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diffusion technology co Ltd
Original Assignee
Diffusion technology co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diffusion technology co Ltd filed Critical Diffusion technology co Ltd
Publication of CN109069460A publication Critical patent/CN109069460A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780028973.8A 2016-05-09 2017-05-08 改进的药物制剂 Pending CN109069460A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662333482P 2016-05-09 2016-05-09
US62/333,482 2016-05-09
US201662334576P 2016-05-11 2016-05-11
US62/334,576 2016-05-11
PCT/US2017/031521 WO2017196712A1 (en) 2016-05-09 2017-05-08 Improved drug formulations

Publications (1)

Publication Number Publication Date
CN109069460A true CN109069460A (zh) 2018-12-21

Family

ID=60267508

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780028973.8A Pending CN109069460A (zh) 2016-05-09 2017-05-08 改进的药物制剂

Country Status (10)

Country Link
US (1) US20200009060A1 (enExample)
EP (2) EP3454847A4 (enExample)
JP (2) JP7112333B2 (enExample)
CN (1) CN109069460A (enExample)
AU (1) AU2017262586B2 (enExample)
CA (1) CA3022878C (enExample)
IL (1) IL262745B (enExample)
MA (1) MA44987A (enExample)
WO (1) WO2017196712A1 (enExample)
ZA (1) ZA201807446B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111511365A (zh) * 2017-11-10 2020-08-07 分散技术有限责任公司 改进的药物制剂
CN114190538A (zh) * 2021-12-21 2022-03-18 郑州轻工业大学 一种促β′晶型形成的油脂促结晶剂及应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021086565A1 (en) * 2019-11-01 2021-05-06 Dispersol Technologies, Llc Weakly basic drug and ionic polymer pharmaceutical formulations and methods of formation and administration thereof
WO2021182467A1 (ja) * 2020-03-11 2021-09-16 沢井製薬株式会社 顆粒及びそれを用いた製剤
WO2022094817A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Pharmaceutical formulation
NL2028762B1 (en) * 2021-07-16 2023-01-23 Seranovo Holding B V Micelle-generating formulations for enhanced bioavailability
CN116173018A (zh) * 2021-11-26 2023-05-30 上海宣泰医药科技股份有限公司 一种达罗他胺药物组合物及其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835492A (zh) * 2007-08-21 2010-09-15 德克萨斯州立大学董事会 用于制药应用的热动力学混合
CN102083418A (zh) * 2008-04-24 2011-06-01 伊万斯彻有限公司 口服避孕药剂及其制备方法
WO2012116238A1 (en) * 2011-02-23 2012-08-30 Dispersol Technologies, Llc PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-β-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS
WO2014170026A1 (en) * 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1165291C (zh) * 1996-05-20 2004-09-08 詹森药业有限公司 具有改进的生物利用度的抗真菌组合物
AU2007226983A1 (en) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
KR20100126452A (ko) * 2008-02-28 2010-12-01 바이알 - 포르텔라 앤드 씨에이 에스에이 난용성 약물용 약학적 조성물
WO2009140105A2 (en) * 2008-05-14 2009-11-19 Merck & Co., Inc. Formulations for cathepsin k inhibitors
ES2688278T3 (es) * 2010-05-10 2018-10-31 Evonik Röhm Gmbh Forma de dosificación farmacéutica que comprende uno o más ingredientes activos antirretrovirales
CN103491964A (zh) * 2011-03-08 2014-01-01 扎里卡斯药品有限公司 固体分散体制剂及其使用方法
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
EP3131667B1 (en) * 2014-04-18 2021-09-01 Dispersol Technologies, LLC Multiple speed process and mixer for preserving heat sensitive portions of a thermokinetically melt blended batch
WO2015175505A1 (en) * 2014-05-15 2015-11-19 Lundbeck Llc Tetrabenazine modified release formulation
US20170333404A1 (en) * 2014-11-03 2017-11-23 Dispersol Technologies, Llc Improved formulations of vemurafenib and methods of making the same
CN104434809B (zh) * 2014-12-10 2018-10-16 北京科莱博医药开发有限责任公司 一种奥拉帕尼固体分散体制剂及其制备方法
BR102017011025A2 (pt) * 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835492A (zh) * 2007-08-21 2010-09-15 德克萨斯州立大学董事会 用于制药应用的热动力学混合
CN102083418A (zh) * 2008-04-24 2011-06-01 伊万斯彻有限公司 口服避孕药剂及其制备方法
WO2012116238A1 (en) * 2011-02-23 2012-08-30 Dispersol Technologies, Llc PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-β-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS
WO2014170026A1 (en) * 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ZHU, Y ET AL.: "Influence of a lipophilic thermal lubricant on the processing conditions and drug release properties of chlorpheniramine maleate tablets prepared by hot-melt extrusion", 《JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY》 *
杨明山: "《塑料改性实用技术与应用》", 30 June 2014, 印刷工业出版社 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111511365A (zh) * 2017-11-10 2020-08-07 分散技术有限责任公司 改进的药物制剂
CN114190538A (zh) * 2021-12-21 2022-03-18 郑州轻工业大学 一种促β′晶型形成的油脂促结晶剂及应用
CN114190538B (zh) * 2021-12-21 2023-11-24 郑州轻工业大学 一种促β′晶型形成的油脂促结晶剂及应用

Also Published As

Publication number Publication date
JP7458440B2 (ja) 2024-03-29
IL262745A (en) 2018-12-31
ZA201807446B (en) 2025-05-28
US20200009060A1 (en) 2020-01-09
MA44987A (fr) 2019-03-20
JP2019514993A (ja) 2019-06-06
IL262745B (en) 2022-07-01
EP4552641A2 (en) 2025-05-14
AU2017262586B2 (en) 2023-04-13
CA3022878C (en) 2024-04-30
JP7112333B2 (ja) 2022-08-03
EP3454847A1 (en) 2019-03-20
EP4552641A3 (en) 2025-07-30
WO2017196712A1 (en) 2017-11-16
EP3454847A4 (en) 2019-12-18
CA3022878A1 (en) 2017-11-16
JP2022116234A (ja) 2022-08-09
AU2017262586A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
CN109069460A (zh) 改进的药物制剂
CN101594851B (zh) 用于口服给药的酪氨酸激酶抑制剂的药物剂型
EP3498264B1 (en) Pharmaceutical preparation for oral administration with controlled dissolution rate, the preparation comprising tamsulosin hydrochloride-containing sustained-release pellets
TW200848056A (en) Solid dispersion of a neurokinin antagonist
EP1957048A2 (de) Feste, oral applizierbare pharmazeutische darreichungsformen mit schneller wirkstofffreisetzung
WO2012116238A1 (en) PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-β-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS
WO2010078429A1 (en) Pharmaceutical dosage forms and methods of manufacturing same
CN107847490A (zh) 改进的地拉罗司制剂及制备其的方法
CN117337170A (zh) 包含(4s)-24-氯-4-乙基-73-氟-35-甲氧基-32,5-二氧代-14-(三氟甲基)-32h-6-氮杂-3(4,1)-吡啶-1(1)-[1,2,3]三唑-2(1,2),7(1)-二苯七蕃-74-甲酰胺的药物剂型
US20250360085A1 (en) Improved drug formulations
AU2016373574B2 (en) Pharmaceutical compositions comprising phenylaminopyrimidine derivative
WO2025214247A1 (zh) 恩扎卢胺药物组合物及其制备方法和用途
US9555026B2 (en) Solid dispersion comprising amorphous cilostazol
US20100317642A1 (en) Pharmaceutical composition of orlistat
RU2723255C2 (ru) Экструдат с микофенолятом натрия для получения пероральной твердой лекарственной формы
CN101252919B (zh) 具有改良溶解曲线的药片
HK40000762A (en) Improved drug formulations
Venkatesan et al. Pharmaceutical polymers
CN117979959A (zh) 药物组合物及其制备方法
Bambharoliya Development of controlled release coating system for highly soluble drug matrix tablets of an antidiabetic category (PH0168)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40000762

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20181221

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40000762

Country of ref document: HK